Columbia’s researchers have opened a trial of a noninvasive, focused ultrasound approach to open the blood-brain barrier, enabling higher concentrations of an effective drug to enter the brain.
In the past decade, physicians have recommended that women undergoing some surgeries have their fallopian tubes removed at the same time to prevent ovarian cancer.
A significantly lower proportion of Hispanic and Black women who underwent screening received 3D mammograms, according to a new study presented at the 2022 San Antonio Breast Cancer Symposium.
The HPV vaccine has great potential to reduce the rate of cervical cancer in Africa, where Columbia researchers are trying to increase vaccination rates with texts.
Cancer patients are especially vulnerable to COVID and would benefit from the protection the vaccine offers, says Gary Schwartz, MD, deputy director of the Herbert Irving Comprehensive Cancer Center.
A new study has found that up to 20% of aggressive brain cancers are fueled by overactive mitochondria and new drugs in development may be able to starve the cancers.
A new study conducted at Columbia and other centers found that 80% of patients with a type of slow-growing lymphoma achieved a complete remission with a single infusion of CAR T-cell immunotherapy.
For multiple myeloma patients with RAS mutations, inhibiting an enzyme involved in cell proliferation may help patients resistant to current therapies, a new Columbia study has found.
Columbia researchers characterized a new class of ‘biomimetic’ drugs that plug a calcium channel implicated in the development of cancer and several other diseases.
New combination chemotherapies have improved survival for patients with pancreatic cancer, and oncologist Gulam Manji sees early signs that new treatments in trials may be even better.
Columbia researchers have identified a gene signature in localized prostate cancer that predicts the cancer’s odds of spreading and its response to a common treatment for advanced disease.
Immunotherapy, often ineffective against stomach cancer, was more effective when combined with chemotherapy and given earlier, finds a new study in mice.